If you have been reading about mass spectrometry and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-05-22. Numbers and descriptions here follow the published literature rather than marketing material.
Batch-to-batch consistency depends on solid-phase peptide synthesis and subsequent purification. Coupling efficiency, resin choice, and cleavage conditions all affect the final profile. Counter-ion content and moisture can shift the apparent mass of a batch. Documentation typically includes a certificate of analysis with chromatograms and spectra. Independent verification by a second laboratory is sometimes requested. Whether a given certificate reflects the actual vial contents depends on chain of custody. Analytical methods themselves carry uncertainty that should be stated alongside results.
Lyophilized material is typically stored at minus twenty degrees Celsius or lower. Keeping the vial dry and protected from light preserves peptide integrity. Repeated freeze-thaw cycles can cause aggregation or loss of activity. Once dissolved, solutions are generally kept at two to eight degrees Celsius. Stability data for reconstituted solutions vary, and long-term behavior is not fully established. Working aliquots reduce the number of times a stock container is opened.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | Reverse-phase HPLC | Reported as area percentage |
| Identity confirmation | Mass spectrometry | Electrospray or laser desorption |
| Powder storage | Minus 20 degrees Celsius or lower | Dark and dry conditions |
| Solution storage | Two to eight degrees Celsius | Avoid repeated freeze-thaw |
| Appearance | White to off-white powder | Common lyophilized form |
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
== History == Orexigen Therapeutics submitted a New Drug Application (NDA) for the combination to the FDA in March 2010. Having paid a fee under the Prescription Drug User Fee Act, Orexigen was given a deadline for the FDA to approve or reject the drug of January 2011. In December 2010, an FDA Advisory Committee voted 13–7 to approve Contrave and 11–8 to conduct a post-marketing cardiovascular outcomes study. Subsequently, on 2 February 2011, the FDA rejected the drug, and it was decided that an extremely large-scale study of the long-term cardiovascular effects of Contrave would be needed before approval could be considered. It was ultimately approved in the United States in 2014. In December 2014, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency endorsed the combination for licensure as an obesity medication when used alongside diet and exercise. Authorization was granted in March 2015. A review of Mysimba was completed by the CHMP in March 2025. In May 2015, Orexigen prematurely ended the trial that was intended to test whether naltrexone/bupropion increased the risk of major adverse cardiovascular events in obese patients with cardiovascular disease because an independent panel of experts said that the drug maker "inappropriately" compromised the trial by prematurely releasing interim data. The early data release reported a reduction in heart attacks, but that advantage was no longer observed when a more complete view of the data was analyzed.
where Fi is blood flow (noted Q in the Figure above), Cart incoming arterial blood concentration, Pi the tissue over blood partition coefficient and Vi the volume of compartment i. A complete set of differential equations for the 7-compartment model shown above could therefore be given by the following table:
is a constant in dilute solutions, an equilibrium constant value determined using the third option will simply be proportional to the values obtained with the first two. It is common practice in biochemistry to quote a value with a dimension as, for example, "Ka = 30 mM" in order to indicate the scale, millimolar (mM) or micromolar (μM) of the concentration values used for its calculation.
Growth that might also influence this would be large increases or drops in bodyweight/size due to fluctuations of fat (liposuction, rapid fat loss or gain) and/or muscle content (bodybuilding, anabolic steroids, catabolisis/starvation). It can also occur in those that gain new levels of flexibility, stretching, and contortion. A limb's being in a new range of motion never experienced (or at least, not for a long time since youth perhaps) can disrupt one's sense of location of that limb. Possible experiences include suddenly feeling that feet or legs are missing from one's mental self-image; needing to look down at one's limbs to be sure they are still there; and falling down while walking, especially when attention is focused upon something other than the act of walking.
=== Future directions === Over the last three decades, MOFs have been greatly refined and utilized in a wide range of applications. It has been speculated that the integration of artificial intelligence tools into MOF research could lead to the discovery of applications with the potential to solve modern energy and environmental challenges, though currently no public research exists to back this speculation.
Sources: en.wikipedia.org
In the first reaction a fluoride ion, F−, gives up an electron pair to boron trifluoride to form the product tetrafluoroborate. Fluoride "loses" a pair of valence electrons because the electrons shared in the B—F bond are located in the region of space between the two atomic nuclei and are therefore more distant from the fluoride nucleus than they are in the lone fluoride ion. BF3 is a Lewis acid because it accepts the electron pair from fluoride. This reaction cannot be described in terms of Brønsted theory because there is no proton transfer. The second reaction can be described using either theory. A proton is transferred from an unspecified Brønsted acid to ammonia, a Brønsted base; alternatively, ammonia acts as a Lewis base and transfers a lone pair of electrons to form a bond with a hydrogen ion. The species that gains the electron pair is the Lewis acid; for example, the oxygen atom in H3O+ gains a pair of electrons when one of the H—O bonds is broken and the electrons shared in the bond become localized on oxygen. Depending on the context, a Lewis acid may also be described as an oxidizer or an electrophile. Organic Brønsted acids, such as acetic, citric, or oxalic acid, are not Lewis acids. They dissociate in water to produce a Lewis acid, H+, but at the same time, they also yield an equal amount of a Lewis base (acetate, citrate, or oxalate, respectively, for the acids mentioned). This article deals mostly with Brønsted acids rather than Lewis acids.
The US Navy dispatched two naval battle groups built around the aircraft carriers USS Dwight D. Eisenhower and USS Independence to the Gulf, where they were ready by 8 August. The US sent the battleships USS Missouri and USS Wisconsin. 48 US Air Force F-15s from the 1st Fighter Wing at Langley Air Force Base, Virginia, landed in Saudi Arabia and commenced round-the-clock air patrols of the Saudi–Kuwait–Iraq border to discourage Iraqi military advances. They were joined by 36 F-15 A-Ds from the 36th Tactical Fighter Wing at Bitburg, Germany. The Bitburg contingent was based at Al Kharj Air Base. The 36th TFW would be responsible for 11 confirmed Iraqi Air Force aircraft shot down during the war. Two Air National Guard units were stationed at Al Kharj Air Base, the South Carolina Air National Guard's 169th Fighter Wing flew bombing missions with 24 F-16s flying 2,000 combat missions and dropping four million pounds (1,800,000 kilograms; 1,800 metric tons) of munitions, and the New York Air National Guard's 174th Fighter Wing from Syracuse flew 24 F-16s on bombing missions. Military buildup continued, reaching 543,000 troops, twice that used in the 2003 invasion. Much of the material was airlifted or carried to the staging areas via fast sealift ships, allowing a quick buildup. Amphibious exercises were carried out in the Gulf, including Operation Imminent Thunder, which involved the USS Midway and 15 other ships, 1,100 aircraft, and a thousand Marines.
== Applications == Enteropeptidase's specificity makes it an ideal tool in biochemical applications; a fusion protein containing a C-terminal affinity tag (such as poly-His) linked by this sequence can be cleaved by enteropeptidase to obtain the target protein following protein purification. On the converse, the N-terminal pro-sequence of proteases that must be cleaved prior to activation can be mutated to enable activation with enteropeptidase.
Statistical analysis of voting asserted that despite continued counting, the projections were already set and new ballots would not sway the outcomes of any of the states and D.C. The Cybersecurity and Infrastructure Security Agency director Jen Easterly refuted the false claims, and wrote in a statement that there was "no evidence of any malicious activity that had a material impact on the security or integrity of our election infrastructure". Another false claim alleges Musk used the satellite Internet constellation Starlink to change the results of the election. Chief technology officer Chip Trowbridge of voting system manufacturer Clear Ballot dismissed the claim and added that no machines used to scan voting ballots have any network connection whatsoever.
Although follicles were previously thought gone in areas of complete baldness, they are more likely dormant, as recent studies have shown the scalp contains the stem cells from which the follicles arose. Research on these follicular stem cells may lead to successes in treating baldness through hair multiplication (HM), also known as hair cloning. Per a May 2015 review, no successful strategy to generate human hair follicles, for hair regrowth, from adult stem cells has yet been reported. However, in April 2016, scientists from Japan published results of their work in which they created human skin from induced pluripotent stem cells; implanted into laboratory mice, the cells generated skin with hair and glands.
Sources: en.wikipedia.org
Supratrochlear nerve and the supraorbital nerve from the ophthalmic division of the trigeminal nerve Greater occipital nerve (C2) posteriorly up to the vertex Lesser occipital nerve (C2) behind the ear Zygomaticotemporal nerve from the maxillary division of the trigeminal nerve supplying the hairless temple Auriculotemporal nerve from the mandibular division of the trigeminal nerve The innervation of scalp can be remembered using the mnemonic 'Z-GLASS' for Zygomaticotemporal nerve, Greater occipital nerve, Lesser occipital nerve, Auriculotemporal nerve, Supratrochlear nerve, and Supraorbital nerve. The motor innervation of the scalp, specifically, the occipitofrontalis muscle, is split into two main factions: the frontal belly or frontalis muscle is supplied by the temporal branch of facial nerve, while the occipital belly or occipitalis is supplied by the posterior auricular branch of facial nerve.
Tramadol is used primarily to treat mild to severe pain, both acute and chronic. There is moderate evidence for use as a second-line treatment for fibromyalgia, but it is not FDA-approved for this use. Its use is approved for treatment of fibromyalgia as a secondary painkiller by the UK NHS. Its analgesic effects take approximately an hour to be realized, and it takes from two to four hours to reach peak effect after oral administration with an immediate-release formulation. On a dose-by-dose basis, tramadol has about one-tenth the potency of morphine (thus 100 mg is commensurate with 10 mg morphine but may vary) and is practically equally potent when compared with pethidine and codeine. For moderate pain, its effectiveness is roughly equivalent to that of codeine in low doses and hydrocodone at very high doses. For severe pain, it is less effective than morphine. Pain-reducing effects last approximately six hours. The potency of analgesia varies considerably as it depends on an individual's genetics. People with specific variants of CYP2D6 enzymes may not produce adequate amounts of the active metabolite (desmetramadol) for effective pain control.
Because both modern crocodilians and birds have four-chambered hearts (albeit modified in crocodilians), it is likely that this is a trait shared by all archosaurs, including all dinosaurs. While all modern birds have high metabolisms and are endothermic ("warm-blooded"), a vigorous debate has been ongoing since the 1960s regarding how far back in the dinosaur lineage this trait extended. Various researchers have supported dinosaurs as being endothermic, ectothermic ("cold-blooded"), or somewhere in between. An emerging consensus among researchers is that, while different lineages of dinosaurs would have had different metabolisms, most of them had higher metabolic rates than other reptiles but lower than living birds and mammals, which is termed mesothermy by some. Evidence from crocodiles and their extinct relatives suggests that such elevated metabolisms could have developed in the earliest archosaurs, which were the common ancestors of dinosaurs and crocodiles.
A broad array of biological specimens, including blood, urine, gastric contents, oral fluids, hair, and tissues, may undergo analysis. Forensic toxicologists collaborate with pathologists, medical examiners, and coroners to ascertain the cause and manner of death. Human Performance toxicology examines the dose-response relationship between drugs present in the body and their effects. This field plays a pivotal role in shaping and implementing laws related to activities such as driving under the influence of alcohol or drugs. Lastly, Forensic Drug Testing (FDT) pertains to detecting drug use in contexts such as the workplace, sport doping, drug-related probation, and screenings for new job applicants. Identifying the ingested substance ingested is frequently challenging due to the body's natural processes (as outlined in ADME). It is uncommon for a chemical to persist in its original form once inside the body. For instance, heroin rapidly undergoes metabolism, ultimately converting to morphine. Consequently, a thorough examination of factors such as injection marks and chemical purity becomes imperative for an accurate diagnosis. Additionally, the substance might undergo dilution as it disperses throughout the body. Unlike a regulated dose of a drug, which may contain grams or milligrams of the active constituent, an individual sample under investigation may only consist of micrograms or nanograms.
This marked the end of the Druze "divine call", i.e., its active missionary phase. Since then, the Druze have been a closed community, in which neither conversion nor apostasy is allowed. Marriage outside the Druze faith is forbidden and is strongly discouraged, and if a Druze marries a non-Druze, the Druze could be ostracized and marginalized by their community. Because a non-Druze partner cannot convert to Druze faith, a couple consisting of a Druze and non-Druze partner cannot have Druze children; the religion can only be passed onto a child born to two Druze parents.
Sources: en.wikipedia.org
The powder is normally held at minus twenty degrees Celsius or below. Light and moisture exposure should be minimized. Repeated warming and cooling cycles are avoided.
Reverse-phase high-performance liquid chromatography is used for purity. Mass spectrometry confirms molecular weight and sequence integrity. Amino acid analysis offers an additional compositional check.
Published stability data for dissolved material are limited and vary with conditions. Refrigerated solutions are generally used within a short period. The exact shelf life depends on concentration, buffer, and handling.
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.